Next Article in Journal
Shared IVIVR for Five Commercial Enabling Formulations Using the BiPHa+ Biphasic Dissolution Assay
Next Article in Special Issue
Topical Treatments and Their Molecular/Cellular Mechanisms in Patients with Peripheral Neuropathic Pain—Narrative Review
Previous Article in Journal
On Absorption Modeling and Food Effect Prediction of Rivaroxaban, a BCS II Drug Orally Administered as an Immediate-Release Tablet
Previous Article in Special Issue
Novel Fluorinated Poly (Lactic-Co-Glycolic acid) (PLGA) and Polyethylene Glycol (PEG) Nanoparticles for Monitoring and Imaging in Osteoarthritis
 
 
Due to scheduled maintenance work on our database systems, there may be short service disruptions on this website between 10:00 and 11:00 CEST on June 14th.
Article

Article Versions Notes

Pharmaceutics 2021, 13(2), 284; https://doi.org/10.3390/pharmaceutics13020284
Action Date Notes Link
article xml file uploaded 21 February 2021 10:19 CET Original file -
article xml uploaded. 21 February 2021 10:19 CET Update https://www.mdpi.com/1999-4923/13/2/284/xml
article pdf uploaded. 21 February 2021 10:19 CET Version of Record https://www.mdpi.com/1999-4923/13/2/284/pdf
article supplementary file uploaded. 21 February 2021 10:19 CET - https://www.mdpi.com/1999-4923/13/2/284#supplementary
article html file updated 21 February 2021 10:21 CET Original file -
article html file updated 25 July 2022 04:23 CEST Update https://www.mdpi.com/1999-4923/13/2/284/html
Back to TopTop